Tags

Type your tag names separated by a space and hit enter

High CHI3L1 expression is associated with glioma patient survival.
Diagn Pathol 2016; 11:42DP

Abstract

BACKGROUND

Survival of glioma patients with the same tumor histology and grade can vary significantly, and some low-grade gliomas transform to a more malignant phenotype. There is a need of molecular signatures, which are better predictors of the patient diagnosis, outcome of treatment, and prognosis than the diagnosis provided by histopathology. We propose CHI3L1 mRNA expression as a prognostic biomarker for patients with glioma.

METHODS

We measured CHI3L1 expression with quantitative real time-polymerase chain reaction (qRT-PCR) in the cohort of 98 patients with different grade glioma: 10 grade I pylocytic astrocytomas, 30 grade II diffuse astrocytomas, 20 grade III anaplastic astrocytomas, and 38 grade IV astrocytomas (glioblastomas). Statistical analyses were conducted to investigate the association between CHI3L1 mRNA expression levels and patient clinical variables.

RESULTS

We demonstrated that mRNA expression of CHI3L1 was evidently higher in glioblastoma than in lower grade glioma tissues. We evaluated correlations between CHI3L1 expression, clinicopathological characteristics, and the outcomes of the patients. Patients with high CHI3L1 expression had a shorter overall survival (p < 0.001).

CONCLUSIONS

Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well. Further investigation will be required to evaluate CHI3L1 value as a molecular marker for astrocytoma prognoses and for novel treatment strategies against all grade astrocytomas.

Authors+Show Affiliations

Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT-50009, Lithuania.Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT-50009, Lithuania.Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT-50009, Lithuania.Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT-50009, Lithuania.Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT-50009, Lithuania.Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT-50009, Lithuania.Laboratory of Neurooncology and Genetics, Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Eiveniu str. 4, Kaunas, LT-50009, Lithuania. paulina.vaitkiene@gmail.com.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27121858

Citation

Steponaitis, Giedrius, et al. "High CHI3L1 Expression Is Associated With Glioma Patient Survival." Diagnostic Pathology, vol. 11, 2016, p. 42.
Steponaitis G, Skiriutė D, Kazlauskas A, et al. High CHI3L1 expression is associated with glioma patient survival. Diagn Pathol. 2016;11:42.
Steponaitis, G., Skiriutė, D., Kazlauskas, A., Golubickaitė, I., Stakaitis, R., Tamašauskas, A., & Vaitkienė, P. (2016). High CHI3L1 expression is associated with glioma patient survival. Diagnostic Pathology, 11, p. 42. doi:10.1186/s13000-016-0492-4.
Steponaitis G, et al. High CHI3L1 Expression Is Associated With Glioma Patient Survival. Diagn Pathol. 2016 Apr 27;11:42. PubMed PMID: 27121858.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High CHI3L1 expression is associated with glioma patient survival. AU - Steponaitis,Giedrius, AU - Skiriutė,Daina, AU - Kazlauskas,Arunas, AU - Golubickaitė,Ieva, AU - Stakaitis,Rytis, AU - Tamašauskas,Arimantas, AU - Vaitkienė,Paulina, Y1 - 2016/04/27/ PY - 2016/01/11/received PY - 2016/04/16/accepted PY - 2016/4/29/entrez PY - 2016/4/29/pubmed PY - 2016/10/13/medline KW - Astrocytoma KW - CHI3L1 KW - Chitinase 3-like 1 KW - Glioma KW - Survival KW - YKL-40 KW - mRNA SP - 42 EP - 42 JF - Diagnostic pathology JO - Diagn Pathol VL - 11 N2 - BACKGROUND: Survival of glioma patients with the same tumor histology and grade can vary significantly, and some low-grade gliomas transform to a more malignant phenotype. There is a need of molecular signatures, which are better predictors of the patient diagnosis, outcome of treatment, and prognosis than the diagnosis provided by histopathology. We propose CHI3L1 mRNA expression as a prognostic biomarker for patients with glioma. METHODS: We measured CHI3L1 expression with quantitative real time-polymerase chain reaction (qRT-PCR) in the cohort of 98 patients with different grade glioma: 10 grade I pylocytic astrocytomas, 30 grade II diffuse astrocytomas, 20 grade III anaplastic astrocytomas, and 38 grade IV astrocytomas (glioblastomas). Statistical analyses were conducted to investigate the association between CHI3L1 mRNA expression levels and patient clinical variables. RESULTS: We demonstrated that mRNA expression of CHI3L1 was evidently higher in glioblastoma than in lower grade glioma tissues. We evaluated correlations between CHI3L1 expression, clinicopathological characteristics, and the outcomes of the patients. Patients with high CHI3L1 expression had a shorter overall survival (p < 0.001). CONCLUSIONS: Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well. Further investigation will be required to evaluate CHI3L1 value as a molecular marker for astrocytoma prognoses and for novel treatment strategies against all grade astrocytomas. SN - 1746-1596 UR - https://www.unboundmedicine.com/medline/citation/27121858/High_CHI3L1_expression_is_associated_with_glioma_patient_survival_ L2 - https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-016-0492-4 DB - PRIME DP - Unbound Medicine ER -